Payment overview · 2025
General Payments
$1,921.39
71 reported records · 18 companies
Healthcare provider profile · identity verified
Isaac N Beshay, MD
Allopathic & Osteopathic Physicians|Family Medicine · COSTA MESA, CA · NPI 1962434241
Verified facts
What the public records show
CMS Open Payments records show Isaac N Beshay, MD received $1,921.39 in general payments during 2025 across 71 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.76 | 23.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $407.09 | 21.2% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $325.72 | 16.9% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.72 | 5.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.19 | 4.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.76 | 4.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $74.43 | 3.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $68.75 | 3.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.48 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.23 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.85 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.57 | 1.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.69 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.09 | 1.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.48 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.74 | 1.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $20.58 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.26 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,921.39 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $325.72 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $301.60 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.29 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.01 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.95 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.88 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.76 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.23 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $74.43 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.75 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.48 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 29 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 364 | 104 |
| Simvastatin | Simvastatin | 348 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 103 |
| Lisinopril | Lisinopril | 276 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 73 |
| Omeprazole | Omeprazole | 212 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 62 |
| Gabapentin | Gabapentin | 177 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 57 |
| Ozempic | Semaglutide | 162 | 29 |
| Losartan Potassium | Losartan Potassium | 152 | 51 |
| Ibuprofen | Ibuprofen | 142 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 130 | 36 |
| Azithromycin | Azithromycin | 124 | 86 |
| Farxiga | Dapagliflozin Propanediol | 120 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 32 |
| Montelukast Sodium | Montelukast Sodium | 100 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 32 |
| Alcohol Pads | Alcohol Antiseptic Pads | 88 | 20 |
| Pregabalin | Pregabalin | 87 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 12 |
| Jardiance | Empagliflozin | 85 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 20 |
| Carvedilol | Carvedilol | 75 | 21 |
| Mounjaro | Tirzepatide | 73 | 12 |
| Furosemide | Furosemide | 72 | 24 |
| Glipizide | Glipizide | 67 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 60 | 19 |
| Famotidine | Famotidine | 59 | 18 |
| Ketoconazole | Ketoconazole | 59 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 18 |
| Trazodone Hcl | Trazodone Hcl | 59 | 20 |
| Eliquis | Apixaban | 58 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Memantine Hcl | Memantine Hcl | 55 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 54 | 12 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Ezetimibe | Ezetimibe | 53 | 18 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Allopurinol | Allopurinol | 45 | 13 |
| Meloxicam | Meloxicam | 45 | 11 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 37 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Naproxen | Naproxen | 36 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Mupirocin | Mupirocin | 34 | 27 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 22 |
| Linzess | Linaclotide | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 21 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Tramadol Hcl | Tramadol Hcl | 22 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,921.39 · 71 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, Natroba, OFEV, OTEZLA, Omnipod, Ozempic, REPATHA, ROTATEQ, SHINGRIX, Spinosad, TEPEZZA, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error